US4327051011 - Common Stock
HILLSTREAM BIOPHARMA INC
NASDAQ:HILS (9/22/2023, 7:03:56 PM)
After market: 0.2308 +0 (+0.13%)0.2305
+0.01 (+2.76%)
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. The company is headquartered in Bridgewater, New Jersey and currently employs 1 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The firm uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The Company’s pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.
HILLSTREAM BIOPHARMA INC
1200 Route 22 East, Suite 2000
Bridgewater NEW JERSEY
P: 19089553140.0
Employees: 1
Website: https://hillstreambio.com/
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an...
We're starting off the workweek right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) --...
Management will present and hold virtual 1-on-1 meetings with institutional investors and analystsCompany recently announced license and collaboration...
Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting novel epitopes on...
Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing...
Here you can normally see the latest stock twits on HILS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: